Revolutionary Treatment Origins from the Microbiome Sphere by Mbiomics
In the heart of Munich, a tech-bio startup named Mbiomics is making waves in the biotech industry. Founded by physicists and experienced biotech entrepreneurs Johannes B. Woehrstein and Heinrich Grabmayr, the company is on a mission to transform the treatment of immune-related and neurodegenerative diseases.
Mbiomics offers an end-to-end platform for designing and scaling complex microbiome consortia, a technology that enables the scalable production of complex microbial consortia. This groundbreaking approach is made possible by the startup's proprietary analytics, co-culturing technology, and AI-powered design tools.
The company's current advancements in microbiome-based therapies focus on microbiome engineering using a patented analytics platform. This platform allows for the precise identification and development of bacterial consortia tailored to specific diseases, including immune-related and neurodegenerative conditions.
One unique aspect of Mbiomics' technology is the integration of high-precision fluorescence microscopy-based analysis to determine the molecular composition of the gut microbiome. This detailed insight facilitates not only the selection and design of therapeutic microbial communities but also supports patient monitoring in clinical studies.
Another key feature is the targeted approach to build microbial consortia aimed at specific therapeutic effects, particularly in immuno-oncology, inflammatory bowel diseases, and potentially other immune-related and neurodegenerative diseases. The patented platform enhances the precision and scalability of microbiome engineering.
Mbiomics' platform is capable of creating medicines containing an entire ecosystem of more than 100 different gut bacteria. This innovative technology marks the first TechBio platform for designing, manufacturing, and clinically applying large consortia of live biotherapeutic products (LBPs).
With significant Series A funding of EUR 18 million since 2023, Mbiomics is expanding both its research and product development activities, emphasizing their commitment to advancing in both the European and US markets. Their approach benefits from broader trends in genomics, artificial intelligence, and synthetic biology, which together drive innovation in personalized microbiome-based therapies.
Johannes B. Woehrstein, one of the founders, expresses his desire for more specialized investors in deep tech and life sciences who have the staying power this industry requires. He believes that Munich, with its proximity to excellent research, dense life sciences community, access to talent, and funding programs, creates an excellent ecosystem for biotech startups.
Looking ahead, Johannes envisions Mbiomics entering clinical trials with a pilot product in cancer therapy within a year. This milestone would be a significant step towards realizing the startup's vision of becoming a champion and pioneer for microbiome-based therapies with clinical projects in several diverse disease areas, including immuno-oncology, neurodegenerative, inflammatory, and autoimmune diseases.
[1] Source: Mbiomics press release, [date]
- The tech-bio startup Mbiomics, founded in Munich, is leveraging technology in science and artificial intelligence to engineer microbiome-based therapies for immune-related and neurodegenerative diseases.
- Mbiomics' end-to-end platform utilizes proprietary analytics, co-culturing technology, and AI-powered design tools to create medicines containing an entire ecosystem of over 100 different gut bacteria.
- The company's platform, which is capable of scaling complex microbial consortia, has the potential to revolutionize therapies and treatments for numerous health-and-wellness conditions, such as immuno-oncology, inflammatory bowel diseases, and medical-conditions like neurodegenerative diseases.
- With the support of strategic investors specializing in deep tech and life sciences, Mbiomics aims to advance in both the European and US markets, contributing to the growth and development of the technology sector in the community of Munich.
